Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CCR5 | P51681 | 1/20 | 0.62 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654716 | 1.00 | CCR1 (0.62) | CCR1CHRM2CCR5TBXA2RHRH1 | |
| SCHEMBL15478412 | 1.00 | CCR1 (0.62) | CCR1CHRM2CCR5TBXA2RHRH1 | |
| SCHEMBL651927 | 0.95 | CCR1 (0.55) | CCR1CHRM2CCR5TBXA2RHRH1 | |
| SCHEMBL651928 | 0.95 | CCR1 (0.55) | CCR1CHRM2CCR5TBXA2RHRH1 | |
| SCHEMBL656199 | 0.89 | CCR1 (0.62) | CCR1CHRM2CCR5TBXA2RHRH1 | |
| SCHEMBL656198 | 0.89 | CCR1 (0.62) | CCR1CHRM2CCR5TBXA2RHRH1 | |
| SCHEMBL652856 | 0.85 | CCR1 (0.59) | CCR1CHRM2CCR5TBXA2RHRH1 | |
| SCHEMBL10287629 | 0.85 | CCR1 (0.59) | CCR1CHRM2CCR5TBXA2RHRH1 | |
| SCHEMBL14579823 | 0.85 | CCR1 (0.59) | CCR1CHRM2CCR5TBXA2RHRH1 | |
| SCHEMBL652857 | 0.85 | CCR1 (0.59) | CCR1CHRM2CCR5TBXA2RHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-1688418-B1 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARM INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7541365-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1688418-A2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | CCR1 9/4885CHRM2 747/4885CCR5 4/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | CCR1 9/4885CHRM2 747/4885CCR5 4/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | CCR1 4/4885CHRM2 821/4885CCR5 6/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | CCR1 9/4885CHRM2 747/4885CCR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.